Anlin-Napert Li

Sun Yat-sen University Cancer Center
#ImmunoOncology
Views are my own

[Anlin-Napert Li @AnlinLi]

Congrats to our group on the Cancer Cell publication supporting the “TKI-induced target-to-kill” strategy for EGFR-mutant cancer!😃 https://t.co/kmIfgZCcXk

[Anlin-Napert Li @AnlinLi]

What do #Ivonescimab’s positive results in HARMONi-A and HARMONi-2 trials suggest biologically? Beyond T-cell checkpoint evasion, angiogenesis stands out among many other cancer drivers. Future systems must pinpoint such master driver for each patient.

[The Lancet @TheLancet]

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

🔗 https://t.co/Xb4qnE9GmO

[Anlin-Napert Li @AnlinLi]

...due to the nature of high intra- and inter-tumoral heterogeneity and intricate mechanisms of carcinogenesis and immune escape. In fact, many studies only reveal new layers of complexity or yield contradictory findings.

[Anlin-Napert Li @AnlinLi]

Some thoughts to share: There’s a lot of hype about AI curing cancer and other diseases in the near future. While AI has performed exceptionally well in improving diagnostics and predicting treatment outcomes, we’re still far from a true cure due to cancer’s complexity...

[Anlin-Napert Li @AnlinLi]

Our team presented notable ORR for the B7H3 (an immune checkpoint) ADC YL201 across several tumor types in the subsequent-line setting at #ESMO2024. Surprising benefits were observed for SCLC (ORR 68%).

[Madeleine Armstrong @ByMadeleineA]

Zooming in on efficacy with Medilink's B7-H3 ADC YL201 in SCLC. Looks at least as good as $MRK / $DSNKY ifi-dxd & $GSK / Hansoh project #ESMO24

[Anlin-Napert Li @AnlinLi]

Deeply honored to receive the @myESMO Merit Award this year and to have learned so much! #ESMO2024

[Anlin-Napert Li @AnlinLi]

Our group highlights the future need to differentiate true #irAEs from false ones.
https://t.co/ntiKLms0Us

[Emre Yekedüz @yekeduz_emre]

🤔Discovering the hidden impact of placebos in immune checkpoint inhibitor trials! ⁉️⁉️⁉️

⁉️🚨This meta-analysis reveals that 22.85% of placebo patients reported immune-related adverse events (irAEs), highlighting the need for careful interpretation of irAE profiles.

✴️✅Understanding these 'false' irAEs is crucial for patient safety and accurate trial outcomes.

#Oncology #ClinicalTrials @OncoAlert @NCIResearchCtr @FDAOncology @CR_UK

https://t.co/rHWiVJwcVB

[Anlin-Napert Li @AnlinLi]

Exciting and important data from the HARMONi-A from our director Prof. Li Zhang: Ivonescimab plus chemotherapy improved PFS in EGFR-MUT patients who progressed on TKI, with a good safety profile. We hope to see improvement in OS😀! #ASCO24

[Stephen V Liu, MD @StephenVLiu]

Dr. Li Zhang at #ASCO24 presents phase III HARMONi-A study of chemotherapy + ivonescimab (PD1/VEGF bispecific) vs placebo in pts with #EGFR NSCLC post TKI.

[Anlin-Napert Li @AnlinLi]

Adding #IO in the adjuvant phase to neoadjuvant IO and chemotherapy may not benefit #NSCLC and may be associated with increased AEs.

[JAMA Network Open @JAMANetworkOpen]

Meta-analysis: Adding adjuvant immunotherapy may not improve clinical outcomes for patients with early-stage NSCLC who receive neoadjuvant PD-1 and PD-L1 inhibitors plus chemotherapy and undergo radical surgery. https://t.co/tT6R7rxq5h

[Anlin-Napert Li @AnlinLi]

This oral has also been published online as a full article in @JTOonline (https://t.co/HkjGvzAtSQ). We believe that the findings could provide valuable information regarding #STK11 in #lungcancer cancer. Welcome any questions or discussions! #WCLC2023

[Anlin-Napert Li @AnlinLi]

Thank you so much #WCLC23 #IASLC This has been an incredible experience. I am so happy to have shared our findings, won an education award, and engaged with numerous experts and young oncologists. #STK11 #lungcancer

[Dr Riyaz Shah @DrRiyazShah]

Nice presentation by @AnlinLi showed STK11 deficient phenotype trumps mutation in in predicting poor outcomes from IO. #WCLC23

[Anlin-Napert Li @AnlinLi]

Congratulations! Our chief Prof. Li Zhang presented a first-in-class EGFRxHER3 bispecific #ADC in patients with locally advanced or metastatic solid tumor.

EGFR-MUT NSCLC with prior TKI: ORR 63.2%

#ASCO23 #ASCO2023

[Anlin-Napert Li @AnlinLi]

Our current preliminary findings: single-cell transcriptomics identifies distinct #PD1 blockade resistance landscapes of tumour immune microenvironment among skin cancer subtypes.
https://t.co/Fj0gXoTrmx

[Anlin-Napert Li @AnlinLi]

Our work presented the role of MUC16 mutations in cancer #immunotherapy

[JAMA Oncology @JAMAOnc]

Cohort study identifies MUC16 mutation as an effective biomarker for survival benefit of immune checkpoint inhibitor in patients with non-small-cell lung cancer. https://t.co/N1AhN0nyQW

[Anlin-Napert Li @AnlinLi]

😀Great to see our new publication, which describes comprehensive clinical evidence regarding neoadjuvant chemotherapy versus neoadjuvant #chemoradiotherapy versus surgery alone in resectable #esophageal carcinoma @EClinicalMed

https://t.co/JigRqy0SIu

[Anlin-Napert Li @AnlinLi]

..., which might be due to a low mutation amount but those mutations are highly immunogenetic . On the contrary, some non-responders were assigned an overestimated TMB score, which might be due to a high mutation amount but those mutations are probably non-immunogenetic.

[Anlin-Napert Li @AnlinLi]

Our current publication and others (31843683,32340679) demonstrated that additionally considering variant allele frequency in the calculation of blood tumor mutation burden (#bTMB) would substantially improve the predictive ability for #immunotherapy.

https://t.co/WwvnIQQdIu

[Anlin-Napert Li @AnlinLi]

Future research of predicsion medicine should further refine the TMB calculation by more appropriately assigning numbers to each of mutations. For instance, some patients who could benefit from immunotherapy were assigned an underestimated TMB score (to be continued....)

[Anlin-Napert Li @AnlinLi]

Great to see our study out😀, which determined long non-coding RNA as a promising predictive biomarker for immune checkpoint inhibitor in cancers. #immunotherapy @JAMANetworkOpen @JAMAOnc

https://t.co/DeigMQ5ZVz